Mechanism of Action
GHRP-6 activates GHSR-1a in both the pituitary (driving GH release) and hypothalamus/limbic areas (driving appetite and food-seeking behavior).
Pituitary GH Release
GHRP-6 binding at GHSR-1a on somatotrophs activates Gq signaling, raising intracellular calcium and triggering GH vesicle exocytosis. The GH pulse produced is large and synergistic with GHRH. GHRP-6 was the archetypal compound used to characterize the GHSR-1a receptor.[1]Ghrelin Receptor Pathway and Appetite
GHSR-1a expression in the hypothalamic arcuate nucleus mediates appetite and food-seeking behavior, the physiological role of the endogenous ligand ghrelin/" class="wiki-internal-link">ghrelin. GHRP-6 activates this pathway with high potency, producing the most pronounced hunger stimulation among GHRPs. This effect peaks 30-45 min post-injection and can be intense at doses above 200 mcg.[2]Wound Healing and Anti-inflammatory Effects
A research area distinct from its GH effects: GHRP-6 has demonstrated direct wound healing properties through fibroblast activation, angiogenesis induction, and anti-inflammatory cytokine modulation in dermal and organ injury models, independent of GH elevation.[3]Research Overview
GH Secretion (Original GHRP)
Most StudiedGHRP-6 was the first GHRP to characterize the GH secretagogue receptor pathway and has the largest body of pharmacological literature of any GHRP. At 1 mcg/kg IV, it produces a reproducible GH peak used in research settings. Synergy with GHRH is well-characterized.[1]
Wound Healing
Strong EvidenceCuban research programs have extensively documented GHRP-6 wound healing properties in excisional wound models. Studies show accelerated re-epithelialization, reduced scar formation, and local anti-inflammatory effects. A topical GHRP-6 formulation (Heberprot-P) is approved in Cuba for diabetic foot ulcers.[3]
Appetite Stimulation
Strong EvidenceThe appetite-stimulating effect of GHRP-6 is reproducible and clinically significant. It is the most potent orexigenic GHRP, making it relevant for cachexia, eating disorders, and conditions where anorexia is problematic. Studies confirm 30-60 min hunger peak post-injection that substantially increases caloric intake.[2]
Calculate your GHRP-6 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| GH pulse | 200–300 µg | 2× daily (fasted) | Subcutaneous |
| Wound healing stack | 100 µg | Once daily | Subcutaneous or near site |
| Appetite / bulking context | 200 µg | 30 min before target meals | Subcutaneous |
| Conservative start | 100 µg | Once daily | Subcutaneous |
The appetite spike occurs 30-45 min post-injection. If appetite stimulation is undesired, time injections immediately before meals to direct hunger appropriately. For GH pulse maximization, dose fasted and delay eating 30-45 min post-injection.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
GHRP-6 has a well-characterized safety profile from decades of research.
WADA: Prohibited as a peptide hormone and growth factor.
Appetite stimulation: Intense hunger 30-60 min post-injection is the defining side effect. Can complicate caloric control protocols. Manageable by timing injection immediately before planned meals.
Cortisol/prolactin: Moderately elevated, more than Ipamorelin. Generally well tolerated at research doses.
Clinically approved formulation: Heberprot-P (GHRP-6 topical, Cuba) provides some human safety reference data for wound-healing applications.
References
- [1]Bowers CY, et al. "On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone." Endocrinology. 1984;114(5):1537-1545.
- [2]Tschop M, et al. "Ghrelin induces adiposity in rodents." Nature. 2000;407(6806):908-913.
- [3]Berlanga J, et al. "A selective GHRP-6-derived peptide potently promotes recovery from burn wound." Clin Sci. 2006;111(1):29-36.